Glaukos Co. (NYSE:GKOS) Shares Purchased by Qsemble Capital Management LP

Qsemble Capital Management LP boosted its stake in Glaukos Co. (NYSE:GKOS) by 70.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 4,522 shares of the medical instruments supplier’s stock after purchasing an additional 1,863 shares during the period. Qsemble Capital Management LP’s holdings in Glaukos were worth $535,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in Glaukos by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after purchasing an additional 31,213 shares during the last quarter. Norges Bank acquired a new stake in Glaukos in the 4th quarter valued at approximately $28,807,000. Nomura Holdings Inc. increased its holdings in Glaukos by 3.2% in the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock valued at $18,444,000 after purchasing an additional 7,146 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Glaukos in the 2nd quarter valued at approximately $6,832,000. Finally, Natixis acquired a new stake in Glaukos in the 1st quarter valued at approximately $614,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Activity at Glaukos

In related news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the sale, the director now directly owns 30,119 shares of the company’s stock, valued at $3,614,280. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Marc Stapley sold 6,250 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the completion of the sale, the director now directly owns 34,076 shares of the company’s stock, valued at $4,291,190.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Aimee S. Weisner sold 25,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now directly owns 30,119 shares of the company’s stock, valued at $3,614,280. The disclosure for this sale can be found here. Insiders sold a total of 41,500 shares of company stock valued at $5,099,000 over the last ninety days. Insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS stock opened at $126.28 on Friday. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The firm has a fifty day moving average price of $124.45 and a 200 day moving average price of $109.86. The company has a market cap of $6.94 billion, a P/E ratio of -43.85 and a beta of 1.03. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm had revenue of $95.70 million during the quarter, compared to analysts’ expectations of $88.86 million. During the same period in the previous year, the company earned ($0.55) earnings per share. Glaukos’s quarterly revenue was up 19.0% compared to the same quarter last year. Sell-side analysts predict that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. Citigroup downgraded shares of Glaukos from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $130.00 to $132.00 in a research note on Wednesday, July 10th. Truist Financial restated a “buy” rating and issued a $145.00 price target (up previously from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Morgan Stanley boosted their price target on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Wells Fargo & Company boosted their price target on shares of Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $129.82.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.